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Abstract
Purpose To present the outcomes of ultrasound (US) follow-ups in children with autoimmune thyroid disease who did not 
have a thyroid nodule on admission but developed papillary thyroid carcinoma (PTC) and to characterize the parenchymal 
changes in the thyroid gland prior to the development of PTC.
Methods A retrospective thyroid US scan review of 327 patients diagnosed with AIT was performed. Forty patients (40/327, 
12.2%) presented nodular AIT variant with a normoechogenic background. Eleven patients (11/327, 3.4%, 11/40, 27.5%) 
presenting this variant were diagnosed with PTC (nine females—mean age 15.3 years; two males aged 11 and 13 years). In 
five of 11 patients, the suspicious nodule that was later confirmed to be PTC was detected on the initial US at presentation. 
For the remaining six females (6/11) who developed PTC during the follow-up, we retrospectively analysed their US thyroid 
scans and these patients were selected for analysis in this study.
Results On admission, the US evaluation revealed an enlarged normoechogenic thyroid gland in three patients and a 
hypoechogenic thyroid gland with fibrosis as indicated by irregular, chaotic hyperechogenic layers in three patients. No 
thyroid nodules were identified. Ultrasound monitoring revealed increasing echogenicity of the thyroid parenchyma during 
the follow-up. PTC developed in a mean time of 4.6 years (1 9/12–7 4/12 years) since referral to the outpatient thyroid clinic 
and 2.9 years (6/12–6 9/12) since the last nodule-free US thyroid scan.
Conclusions Sonographic follow-up assessments warrant further exploration as a strategy to determine PTC susceptibility 
in the paediatric population.
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Introduction
Differentiated thyroid carcinoma (DTC) accounts for the 
vast majority of paediatric thyroid cancers [1]. Papillary 
thyroid carcinoma (PTC) accounts for more than 90% of 
all childhood DTC cases [2]. Thyroid cancer is the most 
common paediatric endocrine malignancy in the United 
States [1]. The most recent statistical data estimate a thy-
roid cancer rate of 0.59 per 100,000 patients less than 
19 years of age, with the incidence increasing at a rate 
of approximately 1% per year [3]. The annual incidence 
of thyroid cancer is < 1 case per million/year in children 
under 10 years of age, 3.5 cases per million/year in chil-
dren between the ages of 10 and 14 years, and 15.4 cases 
per million/year in those aged 15–19 years [4–8]. Accord-
ing to the data of the Polish National Cancer Registry from 
2003 to 2013, new cases of thyroid cancer in patients less 
than 19 years of age constitute every second solid neo-
plasm in girls and every eighth solid neoplasm in boys [2].
The prevalence of chronic autoimmune thyroiditis 
(AIT) is reportedly up to 2% in children and almost 10% 
in adolescents and continues to rise [9, 10]. The disease 
has a female predominance, and although observed in 
children up to 3 years of age, it often occurs after the age 
of six and peaks at 10–12 years of age [11]. US surveys 
have reported that 5 of every 1000 children aged between 
11 and 18 years are diagnosed with Hashimoto thyroidi-
tis every year [11]. Not only an increase in the annual 
frequency of AIT between 1975 and 2005 (+ 350% after 
1995) but also progressive decreases in both the age at 
presentation and the female-to-male (F/M) ratio were 
reported in a large Italian study [12].
Autoimmune thyroiditis is responsible for approxi-
mately 55–65% of all paediatric euthyroid goitres [13, 14]. 
It is considered a premalignant lesion with an increased 
prevalence in cancer [15–17].
The sonographic appearance of lymphocytic thyroiditis 
varies, likely reflecting the phase and severity of the disease 
process [12]. In our previous work, we presented five ultra-
sonographic variants of autoimmune thyroiditis in children 
(in decreasing frequency): (1) the most common form of 
diffuse thyroiditis with a hypoechogenic background and 
normoechogenic parenchyma, (2) diffuse thyroiditis with an 
irregular background, (3) a nodular variant with a normoe-
chogenic irregular background, (4) micronodulations, and 
(5) a variant with a diffuse hypoechogenic background [18]. 
We also reported that patients with the nodular AIT variant 
with a normoechogenic irregular background of the thyroid 
gland are at risk of developing PTC and should be followed 
up with regular neck ultrasound (US) assessments [18].
In the general paediatric population, the incidence 
of thyroid nodules is 1–18% [19]. In AIT patients, the 
incidence of thyroid nodules is 13–30% [18–20]. The co-
existence of AIT and PTC ranges between 6.3 and 43% 
depending on the patient population and continues to rise 
[18, 19, 21–25]. In paediatric patients with PTC, Niedziela 
et al. found that the prevalence of autoimmune thyroiditis 
increased tenfold between 1996 and 2000 and 2001–2015 
[26]. Increases in both the PTC incidence and the occur-
rence of PTC with AIT were noted in our centre [14, 18]. 
Thirteen patients with PTC (30.8% with AIT) between 
2000 and 2010 and 20 patients with PTC (55% with AIT) 
between 2010 and 2017 were treated in our centre in Kra-
kow, Lesser Poland [14].
According to the current paediatric guidelines, neck US 
in children with autoimmune thyroid disease should be per-
formed at least every 12 months [2]. Since thyroid US is a 
sensitive and noninvasive procedure, it was incorporated into 
our institutional follow-up protocol for children with thyroid 
disorders. Access to ultrasound in our outpatient endocrine 
clinic enables long-term monitoring of patients in thyroid 
cancer risk groups, including patients with the normoecho-
genic AIT variant.
The present study expands upon the previous works from 
our centre with new observations from ultrasound monitor-
ing of a selected group of AIT patients [14, 18]. The aim of 
this study was to present the outcomes of ultrasound (US) 
follow-ups in children with autoimmune thyroid disease who 
did not have a thyroid nodule on admission but developed 
PTC and to characterize the parenchymal changes in the 
thyroid gland prior to the development of PTC that may be 
useful in identifying a PTC risk group among paediatric 
patients with AIT.
Methods
A retrospective chart and thyroid US scan review of 327 
patients (245 females) diagnosed with autoimmune thy-
roiditis (AIT) between January 2015 and December 2017 
was performed. The mean age of the patients was 13.1 years 
(range 3–19 years). The patients were subdivided according 
to AIT variants (as described before by our group [18]): 
(a) diffuse thyroiditis with a hypoechogenic background 
(114/327, 34.9%), (b) diffuse thyroiditis with an irregular 
background (98/327, 29.9%), (c) micronodulations (65/327, 
19.9%), (d) a nodular AIT variant with a normoechogenic 
background (40/327, 12.2%), and (e) a variant with a diffuse 
hypoechogenic background (10/327, 3.1%).
The nodular AIT variant with a normoechogenic back-
ground was identified in 12.2% (40/327) of the whole group. 
In 29 patients (29/40, 72.5%) with the nodular AIT variant 
with a normoechogenic background, fine-needle aspiration 
biopsy (FNAB) results were benign and corresponded to col-
loid cysts (3/29, 10.3%), ectopic thymic tissue (2/29, 6.9%), 
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and focal AIT (24/29, 82.8%). Eleven patients with the nodu-
lar AIT variant with a normoechogenic background were 
diagnosed with papillary thyroid carcinoma (nine females, 
mean age 15.3 years (range 11–19 years); two males aged 
11 and 13 years). Patients with PTC constituted 27.5% of 
the nodular AIT variant cases and 3.4% of the whole group.
In 5 of 11 patients, the suspicious nodule that was later 
confirmed to be PTC was detected on the initial US at pres-
entation. For the remaining six females (6/11) who devel-
oped PTC during the follow-up at the endocrine outpatient 
department, we retrospectively analysed their US thyroid 
scans, performed between 2009 and 2017, showing paren-
chymal changes in the thyroid gland prior to the develop-
ment of PTC, and these patients were selected for analysis 
in this study.
The analysis included the reason for referral to the endo-
crinologist, age at AIT and PTC diagnosis, thyroid status, 
levels of autoantibodies (TPOAb—thyroperoxidase antibody 
and TgAb—thyroglobulin antibody), US features of the 
thyroid gland at presentation (with the date and age of the 
patient) prior to PTC diagnosis, and US features at the initial 
detection of the nodule (with the date and age of patient).
AIT was confirmed in six patients based on clinical fea-
tures (presence of goitre, firm consistency of the thyroid 
gland), hormonal features (hypothyroidism or subclinical 
hypothyroidism), and increased TPOAb and/or TgAb lev-
els. Compensated (or subclinical) hypothyroidism was diag-
nosed if the TSH level was above the upper normal range (n: 
0.4–4.0 µIU/ml) and fT4 was close to the low normal range 
(n: 10–25 pmol/l). Ultrasonography of the thyroid gland was 
performed to determine the AIT variant.
US of the thyroid gland was performed at the Univer-
sity Children’s Hospital by board US-certified doctors (DJ, 
PS, and ŁW). Thyroid US was performed using a high-
resolution Voluson 730 GE Medical System (8–12-MHz 
linear transducer), Philips Epiq5 (L12-5 linear transducer), 
Philips iE22 (L11-3 linear transducer), and Logiq P6, GE 
Healthcare (11L linear transducer). The US examination 
was performed in the transversal and longitudinal planes. 
Scans indicating background parenchymal echogenicity 
were reviewed retrospectively. Normal thyroid parenchyma 
(normoechogenic background) was defined as demonstrat-
ing homogenous echogenicity and relative hyperechogenic-
ity compared with the adjacent sternohyoid, sternothyroid, 
omohyoid, and sternocleidomastoid muscles as described 
previously [18]. Abnormal parenchymal features of the thy-
roid gland, including irregular echotexture, micronodular-
ity, and diffuse or focal hypoechogenic lesions and nodules, 
were also evaluated.
Patients presenting a nodule with suspicious features, 
such as hypoechogenicity, a hyperechogenic `border` 
between a nodule and the thyroid parenchyma, poorly 
defined margins, an irregular shape, microcalcifications, a 
solid structure, vascularity as detected with Doppler flow, 
and/or pathologic lymph nodes, were referred to paediatric 
oncologic surgeons for FNAB. PTC was diagnosed when the 
FNAB results fulfilled the Bethesda criteria [27]. In patients 
with PTC, total thyroidectomy with lateral and central lymph 
node histopathological verification was performed.
Postoperative staging was performed based on the 
tumour, nodes, and metastases (TNM) system proposed by 
the American Joint Committee on Cancer [28].
The study was approved by the Institutional Review 
Board.
Results
The clinical and hormonal data of the patients are presented 
in Table 1.
Ultrasound follow-ups with transversal and longitudinal 
scans of the thyroid glands of all patients are presented in 
Figs. 1, 2, 3, 4, 5, and 6.
All patients were referred for endocrine evaluation 
because of an enlarged thyroid gland. Thyroid palpation 
revealed diffuse firm goitre in all cases.
On admission, the US evaluation revealed an enlarged 
normoechogenic thyroid gland in three patients and a 
hypoechogenic thyroid gland with fibrosis as indicated by 
irregular, chaotic hyperechogenic layers in three patients. 
The median thyroid volume was 10.5 ml (range 5.6–21.7 ml, 
the reference thyroid volume data for age and gender are 
presented in Table 1 and separately for individual patients). 
At the time of the initial US, no thyroid nodules were identi-
fied in the study group.
One patient was diagnosed with hypothyroidism (patient 
5), and five patients were diagnosed with subclinical hypo-
thyroidism. Because of the presence of a goitre and abnor-
mal thyroid function, all patients received therapy with levo-
thyroxine. TPOAb levels were increased in five patients (1, 
3–6). In patient 2, the TPOAb level was within the normal 
range, but the TgAb level was increased, thus confirming 
autoimmunity (Table 1).
Ultrasound monitoring revealed increasing echogenic-
ity of the thyroid parenchyma in relation to the adjacent 
sternothyroid, sternohyoid, sternocleidomastoid, and omo-
hyoid muscles in all patients during the follow-up. Finally, 
in all patients, malignant nodules developed in the thyroid 
gland with a normoechogenic background without typical 
ultrasound AIT features such as diffuse hypoechogenicity 
or micronodulations as demonstrated in our previous study 
[18]. Papillary thyroid carcinoma developed in a mean 
time of 4.6 years (1 9/12–7 4/12 years) since referral to 
the outpatient thyroid clinic and 2.9 years (6/12–6 9/12) 
since the last nodule-free US thyroid scan (Figs. 1, 2, 3, 
4, 5, 6). The median maximum nodule size on US was 
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9.4 mm (range: 6.7–16.4 mm) and the growth rate of the 
nodules was fast (Figs. 1, 2, 3, 4, 5, and 6). The volume 
of the nodule increased by 82% at 6 months in Patient 1, 
92% at 1 month in Patient 2, 84% at 1 month in Patient 3, 
132% at 8 months in Patient 5, and 316% at 7 months in 
Patient 6 during observation in the outpatient clinic before 
FNAB was performed.
In five patients, the nodules were hypoechogenic. In four 
of these patients, the nodules were surrounded by a hyper-
echogenic ‘margin’, and in one patient, the nodule had mixed 
echogenicity and an irregular lobulated border. No microcal-
cifications were observed in the nodules. The vascularization 
of the nodules was centralized and increased in relation to 
the surrounding thyroid parenchyma.
Table 1  Clinical and hormonal data of patients
ATA (The American Thyroid Association) pediatric risk group: I—low risk, II— intermediate risk, and III—high risk [39]
AACE/ACE/AME (The American Association of Clinical Endocrinologists, American College of Endocrinology and Associazione Medici 
Endocrinologi) US Classification System: Class 1—Low-risk thyroid lesion; Class 2—Intermediate-risk thyroid lesion; Class 3—High-risk thy-
roid lesion [40]
TPOAb thyroperoxidase antibody, TgAb thyroglobulin antibody, AIT autoimmune thyroiditis, PTC papillary thyroid carcinoma, TNM tumour, 
nodes, and metastases system
a Thyroid volume references [41, 42]
Patient 1 2 3 4 5 6
Age at AIT diagnosis (years) 11 11/12 9 3/12 9 8/12 9 6/12 12 6/12 11 8/12
Age (years) and
date (DD-MM-YYYY) of US at 
presentation
12
23-03-2011
9 3/12
8-08-2015
10 4/12
28-12-2010
9 9/12
27-12-2011
15 5/12
10-07-2015
11 8/12
28-05-2009
Thyroid volume (ml)a 10 ml
(N < 9.5)
11 ml
(N < 5.4 ml)
5.6 ml
(N < 5.4 ml)
8.2 ml
(N < 5.4 ml)
17.7 ml
(N < 10.9)
21.7
(N < 9.5)
TSH at AIT diagnosis (µIU/
ml N: 0.4–4.0)
5.01 6.6 4.8 8 18.2 9.2
fT4 at AIT diagnosis
(pmol/l N: 10–25)
11.2 11.1 12.1 10.7 9.7 10.3
TPOAb at AIT diagnosis (IU/
ml N < 30)
1271.7 10.9 > 1300 226.6 > 1000 > 9000
TgAb at AIT diagnosis
(U/ml N < 30)
– 195 154.3 – – > 1000
Age (years) and
date (DD-MM-YYYY) of US at 
first detection of the nodule
16 8/12
16-11-2015
11
15-05-2017
14 10/12
06-06-2015
13 6/12
09-09-2015
16 9/12
30-11-2016
18 5/12
11-02-2016
Age at PTC diagnosis (years) 16 11/12 11 14 10/12 13 6/12 17 5/12 19
Thyroid volume at PTC diagno-
sis (ml)
16 ml
(N < 18 ml)
14.9 ml
(N < 9.5 ml)
6.4 ml
(N < 16.1)
11.8
(N < 13.1 ml)
6.0 ml
(N < 18 ml)
9.3 ml
(N < 18 ml)
Nodule size on US scan (mm) 10.8 × 10.4 × 16.4 6.5 × 4.7 × 6.7 7 × 5 × 6 8 × 8 × 9 6.6 × 9.8 × 4.1 12.2 × 7.4 × 8.9
TSH at PTC dgn
(µIU/ml N: 0.4–4.0)
0.7 7 2.9 1.5 3.5 0.7
fT4 at PTC diagnosis
(pmol/l N:10–25)
16.8 9.2 16.7 19.3 15.3 19.8
TPOAb at PTC dgn
(IU/ml N < 30)
– 167.7 925.9 126.2 1920 245.2
TgAb at PTC dgn
(U/ml N < 30)
– 93.4 21.1 154.3 467.5 404.2
Time to PTC detection since 
referral (years)
5 1 9/12 4 10/12 4 4 11/12 7 4/12
Time to PTC detection since 
last nodule-free US scan 
(years)
4 8/12 10/12 6/12 3 9/12 1 4/12 6 9/12
AACE/ACE/AME risk group Class 3 Class 3 Class 3 Class 3 Class 3 Class 3
TNM pT1aN0M0 pT1aN0M0 pT1aN0M0 pT1aN1aM0 pT1aN0M0 pT1aN0M0
ATA risk group I I I II I I
PTC variant Classic Follicular Classic, solid, follicular Classic, follicular Classic Classic
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Apart from one non-compliant patient who stopped 
levothyroxine treatment for 1 year (Patient 2), in all cases, 
decreases in goitre volume were observed at the time of PTC 
diagnosis from a median volume of 10 ml (5.6–21.7 ml) on 
US at presentation to a median of 9.3 ml (6–16 ml). The 
median TSH levels decreased from 8 µIU/ml (5.01–18.2) to 
1.5 µIU/ml (0.7–7.0).
After FNAB confirmation according to the Bethesda cri-
teria (category V-suspicious for malignancy) [27], total thy-
roidectomy with central and lateral lymph node dissection 
was performed in all patients.
TNM classification revealed pT1aN0M0 in 5/6 patients, 
and these patients did not receive  I131 therapy. Only Patient 
4 was classified as pT1aN1aM0 with a nodule < 10 mm and 
received radionuclide therapy.
The classic PTC variant was found in three patients, the 
follicular PTC variant was found in one patient, and mixed 
variants were found in two patients: classic/solid/follicular 
and classic/follicular (Table 1).
After surgery, the outcomes of therapy were favour-
able. No complications after thyroidectomy were noted. All 
patients are currently followed up at the Institute of Oncol-
ogy and are in remission. Tg and TgAb levels are negative 
in all cases.
Discussion
To our knowledge, this is the first report of ultrasound pres-
entations of parenchymal changes in the thyroid gland in 
young patients with autoimmune thyroiditis evaluated sono-
graphically prior to the development of histologically con-
firmed papillary thyroid carcinoma.
Fig. 1  Patient 1. Transversal (a) and longitudinal (b) scans of the 
hypoechogenic thyroid gland revealed formation of the nodule 
5  years since referral and 4 8/12  years since last ultrasound assess-
ment. The growth of the nodule was fast from 8.1 × 9.5 × 13.1 mm to 
10.8 × 10.4 × 16.4 mm in 6 months (82% increase). During follow-up, 
the echogenicity of the thyroid gland increased
Fig. 2  Patient 2. Transversal (a) and longitudinal (b) scans of 
the hypoechogenic thyroid gland revealed the formation of the 
nodule 1 9/12  years since referral and 10/12  months since last 
ultrasound assessment. The growth of the nodule was fast from 
5.4 × 4.7 × 4.2 mm to 6.5 × 4.7 × 6.7 mm in 1 month (92% increase). 
During follow-up, the echogenicity of the thyroid gland increased
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In the overall group of 327 AIT patients, the distribution 
of sonographic AIT variants was similar to our observation 
in the previous work [18]. A total of 87.8% of the patients 
presented typical US variants of AIT (diffuse thyroiditis 
with a hypoechogenic background, diffuse thyroiditis with 
an irregular background, micronodulations, or a diffuse 
hypoechogenic background) and changes were not observed 
in the parenchyma or the nodules in this group of patients 
during the follow-up [18].
The nodular AIT variant with a normoechogenic back-
ground was identified in 12.2% of the whole group. Eleven 
patients (female predominance) presenting this variant were 
diagnosed with papillary thyroid carcinoma. Patients with 
PTC constituted 27.5% of the nodular AIT variant cases and 
3.4% of the whole group; these results are similar to those 
of other paediatric series [19, 20].
In six females who did not have a thyroid nodule on 
admission but who developed PTC, we have been able to 
retrospectively analyse US thyroid scans presenting paren-
chymal changes in the thyroid gland prior to the develop-
ment of PTC and these patients were chosen for presentation 
in this study.
PTC was detected early via US in our study before the 
nodule was clinically apparent. Four of six confirmed cancer 
cases were associated with thyroid nodules < 1 cm, which 
are difficult to detect by manual palpation alone. The most 
common sonographic presentation of a malignant lesion in 
our group was a solid hypoechoic nodule with an irregu-
lar hyperechoic margin (histopathologically identified as 
fibrosis and lymphocytic infiltration) and without microcal-
cifications. The detected nodules showed fast growth rates 
over time, with volumes that doubled or even tripled within 
6–8 months of observation before FNAB was performed. In 
one patient with a nodule diameter less than 10 mm, metas-
tases to several lymph nodes were detected and this patient 
received radioactive iodine therapy (RAI).
Fig. 3  Patient 3. Transversal scans of the normoechogenic thyroid 
gland revealed the formation of the nodule 4 10/12 years since refer-
ral and 6  months after last ultrasound assessment. The growth of 
the nodule was fast from 5.4 × 4.6 × 4.6  mm to 7 × 5 × 6  mm (84% 
increase) in 1  month. The nodule was surrounded by a hyperecho-
genic border
Fig. 4  Patient 4. Transversal (a) and longitudinal (b) scans of the 
normoechogenic thyroid gland revealed the formation of the nodule 
4 years since referral and 3 9/12 months since last ultrasound assess-
ment. The nodule was surrounded by a hyperechogenic border. Dur-
ing follow-up, the echogenicity of the thyroid gland increased
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Our results suggest that the use of US can increase the 
detection rate of thyroid malignancies in patients with the 
normoechogenic AIT variant who seem to be at a higher 
risk of cancer than the overall population of children with 
autoimmune thyroiditis [18]. This higher risk may justify 
the need for closer monitoring, especially considering the 
rapid growth rate of malignant nodules in young patients. 
Unlike adults, children with papillary thyroid cancer may 
present with more advanced disease and have higher rates 
of local recurrence and distant metastases, even though 
their prognosis is favourable, with overall 10-year survival 
rates of 80–95% [29]. Children have a longer posttreatment 
life expectancy and, therefore, more time for recurrence or 
potential treatment effects to manifest [1]. Recent studies 
Fig. 5  Patient 5. Transversal (a) and longitudinal (b) scans of the 
hypoechogenic thyroid gland revealed the formation of the nodule 4 
11/12 years since referral and 1 4/12 year since last ultrasound assess-
ment. The growth of the nodule was fast from 6.5 × 5.5 × 3.2  mm 
to 6.6 × 9.8 × 4.1 mm in 8 months (132% increase). The nodule was 
surrounded by a hyperechogenic border. During follow-up, the echo-
genicity of the thyroid gland increased
Fig. 6  Patient 6. Transversal (a) and longitudinal (b) scans of the 
normoechogenic thyroid gland revealed formation of the nod-
ule 6 9/12  years since referral and since last ultrasound assess-
ment. The growth of the nodule was fast from 6.3 × 7.3 × 4.2 mm to 
12.2 × 7.4 × 8.9  mm in 7  months (316% increase). The nodule was 
surrounded by a hyperechogenic border
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have confirmed that radioactive iodine (RAI) ablation is 
associated with an increased risk for the development of 
additional malignancies as well as an increase in overall 
mortality for patients with DTC [30]. Frequent US follow-
up examinations enable the early detection of PTC, radical 
surgery, and avoidance of RAI therapy. In our study, five 
of six patients did not receive radionuclide therapy, which 
will probably impact their future quality of life considering 
the long-term side effects associated with RAI [30]. We are 
convinced that certain sonographic features of the thyroid 
gland observed in our follow-up study may facilitate the 
early detection of malignancies.
An ongoing debate in the literature is whether the nodu-
lar variant of AIT with a normoechogenic background indi-
cating the presence of residual thyroid tissue identified in 
patients with PTC is a different type of disease compared 
to diffuse AIT and whether autoimmune thyroiditis is sec-
ondary to cancer in this group of patients [18, 31–34]. As 
presented in our previous study, patients with typical vari-
ants of diffuse AIT more often developed abnormalities of 
thyroid function (overt hypothyroidisms or hyperthyroidism) 
compared to patients with the nodular AIT variant with a 
normoechogenic background [18]. The decreased echogenic-
ity of the parenchyma in diffuse AIT has been shown to be 
related to lymphocyte infiltration and correlated with hypo-
thyroidism [31, 34]. A lower incidence of hypothyroidism in 
patients with nodular AIT and normal background thyroid 
parenchyma was also observed in other studies [33, 34]. Our 
findings are consistent with those of Oppenheimer et al., 
indicating that at least two distinct patterns of AIT exist on 
thyroid sonography: diffuse AIT and nodular AIT [31]. As 
hypothesized by Paparodis et al. and Imam et al., in patients 
with euthyroid/functional AIT and low titres of TPOAb, a 
different immune disorder that does not completely destroy 
the thyroid gland may be present, or cancer may actively 
participate in regulating immunity or autoimmunity (cancer 
immunoediting) [33, 35]. As suggested by Ehlers and Schott, 
the reason for the induced antitumour immune response 
(with increased but low TPOAb or TgAb levels in serum) 
may be the presence of undiagnosed papillary thyroid micro-
carcinomas [32]. Consistent with this observation, Paparo-
dis et al. reported an association between AIT duration and 
PTC development after finding that a shorter AIT dura-
tion was associated with PTC development, while a longer 
duration was not [33]. Interestingly, Italian authors reported 
that the annual increase in the AIT incidence preceded the 
annual increase in the PTC incidence, and suggested that 
environmental influences may have favoured both thyroid 
autoimmune disease and PTC-oriented thyroid oncogenesis 
[36]. The new information reported in our study is consist-
ent with the hypothesis that autoimmune thyroiditis may 
be secondary to thyroid oncogenesis as half of our patients 
exhibited normoechogenic thyroid parenchyma prior to the 
development of PTC. In our study group, three girls had a 
normoechogenic thyroid gland at presentation, and whether 
these findings reflected the early stage of AIT or a normal 
thyroid gland was questionable considering that up to 20% 
of the population has positive thyroid autoantibodies without 
any thyroid disease [31]. AIT was confirmed in our patients 
by the presence of goitre, subclinical hypothyroidism, and 
autoantibodies to thyroglobulin and thyroid peroxidase. 
Follow-up scans did not reveal typical sonographic AIT 
features (micronodularity or decreased echogenicity with 
visible hyperechogenic septations). However, during the 
follow-up, we detected a solitary hypoechogenic nodule that 
was later confirmed to be PTC. Therefore, we suggest that 
not only nodular AIT but also AIT with a normoechogenic 
background on sonography at presentation (with no nodules) 
may be an entirely different clinical entity with an increased 
PTC risk, which warrants further research in the paediatric 
population [18, 31, 33]. Our study also found that during the 
follow-up of hypoechogenic thyroid glands with irregular 
hyperechogenic layers, an increase in echogenicity due to 
parenchymal changes was evident, probably due to fibrosis 
and follicular destruction in the thyroid gland during the 
disease process prior to detection of a nodule [37, 38].
In our AIT cohort, the incorporation of thyroid US fol-
low-ups enabled relatively early detection of thyroid malig-
nancies that were not clinically apparent over a mean of 
4.6 years since referral and AIT diagnosis. The data pre-
sented here are consistent with those of the Italian study by 
Rizzo et al., demonstrating that the lag time between AIT 
diagnosis and PTC detection was approximately 5 years, 
which is very similar to the average value reported in our 
paediatric study [36]. In addition, a novel and practical find-
ing of our study is that the shortest lag time from the last 
nodule-free scan to the detection of a suspicious nodule was 
6 months.
Another point of interest in our study is the observation 
that although all patients received levothyroxine treatment, 
except for one patient, and exhibited decreased goitre vol-
umes and TSH levels, l-thyroxine replacement therapy failed 
to provide any protection from nodule development. This 
finding may support the hypothesis that thyroid oncogen-
esis may precede autoimmunity; however, further research 
on larger series of patients is required to confirm these 
observations.
Several limitations exist in our study. Due to the low 
incidence of PTC in young patients, our sample was small; 
therefore, the study had insufficient power to establish sta-
tistical significance. Nevertheless, we propose that sono-
graphic follow-up assessments warrant further exploration as 
a strategy to determine PTC susceptibility in the paediatric 
population.
In accordance with the ATA and Polish Guidelines, chil-
dren with AIT should undergo US evaluation annually. We 
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are convinced, however, that children with a normoecho-
genic background of the thyroid gland or a hypoechogenic 
background with fibrosis appearing as irregular hyperecho-
genic layers should be considered to have a higher risk of 
cancer and should be followed more closely with more fre-
quent ultrasound evaluations [2, 39].
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